SLC5A2 and type 2 diabetes mellitus: This contrasts with previous literature on T2DM patients where SGLT2 inhibitors are associated with reductions in total body fat.34 Despite a reduction in total body water measured by bioimpedance, there was no significant reduction in hepatic free water content as measured by cT1.